An Open Clinical trial to evaluate the effectiveness of Nilavagai chooranam (Internal)and Thaengai thylam (External)in the management of Karappan (Atopic Dermatitis)in Children

An Open Non Randomized, Single arm, Single centric Clinical trial to evaluate the effectiveness of Nilavagai chooranam (Internal)and Thaengai thylam (External)in the management of Karappan (Atopic Dermatitis)in Children

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/05/053291

Enrollment

Registered

2023-05-31

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L00-L08- Infections of the skin and subcutaneous tissue Health Condition 2: L00-L08- Infections of the skin and subcutaneous tissue

Interventions

Intervention1: Nilavagai chooranam (Internal) Thengai thylam (External): Dose: 3 to 6 years – 300 mg to 500 mg 6 to 8 years – 500 mg to 600 mg 9 to 12 years – 642 mg to 750 mg [According to Young’s

Eligibility

Inclusion criteria

Inclusion criteria: Children of both sexes in the age group of 3 to 12 years with Major criteria (3 of 4 must be met): • Pruritis • Chronic or chronically relapsing dermatitis • Typical morphology and distribution • Personal or family history of atopic disease (asthma, allergic rhinitis, AD) Minor criteria: • Xerosis • Ichthyosis/hyperlinear palms/keratosis pilaris • Elevated serum IgE • Early age of onset • Pruritis when sweating • Food hypersensitivity • White dermographism or delayed blanch to cholinergic agent

Exclusion criteria

Exclusion criteria: 1.K/C/O Scabies 2.H/O Contact dermatitis 3.H/O Seborrheic Dermatitis 4.H/O Psoriasis 5.K/C/O Secondary Bacterial Infections 6.K/C/O Furunculosis 7.K/C/O Neurodermatitis 8.Any other serious illness

Design outcomes

Primary

Measure	Time frame
Effectiveness of the trial drug is measured by EASI score & improvement of the clinical condition will be assured Timepoint: 3 days once	—

Secondary

Measure	Time frame
NIL Timepoint: NIL	—

Countries

India

Contacts

Public ContactDr S ESWARI

National Institute of Siddha, Tambaram sanatorium, Chennai.

mmssiddha@rediffmail.com9940266442

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026